

External Quality Assessment Scheme

***Chlamydia pneumoniae*, antibodies** **Round 1, 2023**

Specimens

Please find enclosed 3 human plasma or serum samples S001, S002 and S003, each 0.4 mL.

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

Examinations

Chlamydia pneumoniae total antibodies
Chlamydia pneumoniae IgG
Chlamydia pneumoniae IgM
Chlamydia pneumoniae IgA
Clinical interpretation

Storage and use

After arrival, the samples should be stored at +2...8 °C, and used as soon as possible, preferably within a week. The samples are ready for use. Analyse as patient samples.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA Coordinator. Report only the results of examinations that are in use in your laboratory. All reported examinations will be scored.

S001



S002



S003



2023-03-14

INSTRUCTIONS

Product no. 5620
LQ757423011-013/FI

Subcontracting: Sample pretesting

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi.

The results should be reported no later than **April 5, 2023.**

The expected results of the round are published in LabScala in the View Reports section by April 11, 2023.

Inquiries

EQA Coordinator
Marsa Järvenpää
marsa.jarvenpaa@labquality.fi

EQA Coordinator
Outi Rauta
outi.rauta@labquality.fi

Labquality Oy
Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280


info@labquality.fi
www.labquality.com



Client report

	No of participants	No of responded participants	Response percentage
Chlamydia pneumoniae, antibodies, March, 1-2023	57	53	93 %

Summary




Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Specimen S001	8	8	100 %	5.7 %	94.3 %
Specimen S002	8	8	100 %	13.7 %	86.3 %
Specimen S003	8	8	100 %	10.6 %	89.4 %
Average:			100 %	10 %	90 %

History	Test nr.	Own success rate	Difference	AVR success rate
Round 2022-4	1-1	100 %	6.2 %	93.8 %
Round 2022-3	1-1	100 %	9.4 %	90.6 %
Round 2022-2	1-1	100 %	4 %	96 %
Round 2022-1	1-1	100 %	3.8 %	96.2 %
Round 2021-4	1-1	100 %	9.2 %	90.8 %
Round 2021-3	1-1	100 %	2.6 %	97.4 %
Round 2021-2	1-1	100 %	8.5 %	91.5 %
Round 2021-1	1-1	100 %	7.1 %	92.9 %


Specimen S001

Specimen S001 success rate



Specimen S001 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	5.4 %	94.6 %	55
	CpnAbG	2	2	100 %	1.9 %	98.1 %	54
	CpnAbM	2	2	100 %	0 %	100 %	53
	CpnAbA	-	-	-	-	75.9 %	29
	Total:	8	8	100 %	5.7 %	94.3 %	191


Specimen S001 Clinical interpretation




- Most likely earlier infection/serological scar
- Most likely acute/recent C. pneumoniae infection
- Laboratory does not give clinical interpretation

Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Most likely earlier infection/serological scar		35		4	4	100 %	0 %	100 %
		A second sample is requested		7	-	-			
		Referred to confirmation		1	-	-			
	Most likely acute/recent C. pneumoniae infection		2		-				0 %
		Referred to confirmation		1	-	-			
		A second sample is requested		1	-	-			
	Laboratory does not give clinical interpretation		18		-				-
	Total:		55		4	4	100 %	5.4 %	94.6 %


Specimen S001 CpnAbG



Specimen S001 CpnAbM



Specimen S001 CpnAbA



OWN DEVICE: CHLA PNEU 2

CpnAbG	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Borderline		1		-				0 %
		Euroimmun Anti-Chlamydia pneumoniae MIF		1					
	<input checked="" type="radio"/> Positive		53		2	2	100 %	0 %	100 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		4					
		Euroimmun Anti-C. pneumoniae ELISA		11					
		Euroimmun Anti-Chlamydia pneumoniae MIF		2					
		Focus Diagnostics Chlamydia MIF		3					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3					
		Novatec NovaLisa C. pneumoniae ELISA		4					
		<input checked="" type="radio"/> Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6					
		Savyon diagnostics Chlamydia SeroFIA		1					
		Savyon Diagnostics SeroCP Quant kit		1					
		Savyon Diagnostics SeroFIA C. pneumoniae		1					
		Siemens Novagnost		2					
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3					
		Vircell Chlamydophila pneumoniae ELISA		2					
		Vircell Chlamydophila pneumoniae VIRCLIA Monotest		6					

	Virion/Serion SERION ELISA classic C. pneumoniae		3						
Total:		54		2	2	100 %	1.9 %	98.1 %	


OWN DEVICE: CHLA PNEU 2

CpnAbM	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		53		2	2	100 %	0 %	100 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		4					
		Euroimmun Anti-C. pneumoniae ELISA		11					
		Euroimmun Anti-Chlamydia pneumoniae MIF		3					
		Focus Diagnostics Chlamydia MIF		2					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3					
		Novatec NovaLisa C. pneumoniae ELISA		4					
		<input checked="" type="radio"/> Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6					
		Savyon diagnostics Chlamydia SeroFIA		1					
		Savyon Diagnostics SeroCP		1					
		Savyon Diagnostics SeroFIA C. pneumoniae		1					
		Siemens Novagnost		2					
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3					
		Vircell Chlamydomphila pneumoniae ELISA		2					
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		6					
		Virion/Serion SERION ELISA classic C. pneumoniae		3					
Total:			53		2	2	100 %	0 %	100 %

CpnAbA	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		22		-				100 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1					
		Euroimmun Anti-C. pneumoniae ELISA		5					
		Euroimmun Anti-Chlamydia pneumoniae MIF		1					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		2					
		Novatec NovaLisa C. pneumoniae ELISA		2					
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		4					
		Savyon Diagnostics SeroCP		1					
		Siemens Novagnost		1					
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3					
		Virion/Serion SERION ELISA classic C. pneumoniae		1					
	Borderline		3		-				0 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1					
		Savyon diagnostics Chlamydia SeroFIA		1					
		Vircell Chlamydomphila pneumoniae ELISA		1					
	Positive		4		-				0 %
		Focus Diagnostics Chlamydia MIF		2					
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		2					
Total:			29		-	-	-	-	75.9 %


Specimen S002

Specimen S002 success rate




Specimen S002 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	23.7 %	76.3 %	55
	CpnAbG	2	2	100 %	0 %	100 %	54
	CpnAbM	2	2	100 %	13.2 %	86.8 %	53
	CpnAbA	-	-	-	-	-	29
	Total:	8	8	100 %	13.7 %	86.3 %	191

Specimen S002 Clinical interpretation




Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Most likely earlier infection/serological scar		29		4	4	100 %	0 %	100 %
		A second sample is requested		7	-	-			
	<input type="radio"/> Most likely acute/recent C. pneumoniae infection		9		-	-			0 %
		Referred to confirmation		3	-	-			
		A second sample is requested		3	-	-			
	<input type="radio"/> Laboratory does not give clinical interpretation		17		-	-			-
	Total:		55		4	4	100 %	23.7 %	76.3 %

Specimen S002 CpnAbG




Positive

Specimen S002 CpnAbM



Negative Borderline Positive

Specimen S002 CpnAbA



Negative Borderline Positive

OWN DEVICE: CHLA PNEU 2

CpnAbG	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		54		2	2	100 %	0 %	100 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		4					
		Euroimmun Anti-C. pneumoniae ELISA		11					
		Euroimmun Anti-Chlamydia pneumoniae MIF		3					
		Focus Diagnostics Chlamydia MIF		3					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3					
		Novatec NovaLisa C. pneumoniae ELISA		4					
	<input checked="" type="radio"/>	Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6					
		Savyon diagnostics Chlamydia SeroFIA		1					
		Savyon Diagnostics SeroCP Quant kit		1					
		Savyon Diagnostics SeroFIA C. pneumoniae		1					
		Siemens Novagnost		2					
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3					
		Vircell Chlamydomphila pneumoniae ELISA		2					
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		6					
		Virion/Serion SERION ELISA classic C. pneumoniae		3					
	Total:		54		2	2	100 %	0 %	100 %

OWN DEVICE: CHLA PNEU 2


CpnAbM	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		46		2	2	100 %	0 %	100 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		3					
		Euroimmun Anti-C. pneumoniae ELISA		11					
		Euroimmun Anti-Chlamydia pneumoniae MIF		3					
		Focus Diagnostics Chlamydia MIF		2					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3					
		Novatec NovaLisa C. pneumoniae ELISA		4					
		<input checked="" type="radio"/> Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6					
		Savyon diagnostics Chlamydia SeroFIA		1					
		Savyon Diagnostics SeroCP		1					
		Savyon Diagnostics SeroFIA C. pneumoniae		1					
		Siemens Novagnost		2					
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3					
		Vircell Chlamydomphila pneumoniae ELISA		1					
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		1					
		Virion/Serion SERION ELISA classic C. pneumoniae		3					
	Borderline		3		-				0 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1					
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		2					
	Positive		4		-				0 %
		Vircell Chlamydomphila pneumoniae ELISA		1					
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		3					
	Total:		53		2	2	100 %	13.2 %	86.8 %

CpnAbA	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		10		-				-
		Euroimmun Anti-C. pneumoniae ELISA		5					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		1					
		Novatec NovaLisa C. pneumoniae ELISA		1					
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		1					
		Savyon Diagnostics SeroCP		1					
		Siemens Novagnost		1					
	Borderline		5		-				-
		Euroimmun Anti-Chlamydia pneumoniae MIF		1					
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		2					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		2					
	Positive		14		-				-
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		2					
		Focus Diagnostics Chlamydia MIF		2					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		1					
		Novatec NovaLisa C. pneumoniae ELISA		1					
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		1					
		Savyon diagnostics Chlamydia SeroFIA		1					

		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		1					
		Vircell Chlamydophila pneumoniae ELISA		1					
		Vircell Chlamydophila pneumoniae VIRCLIA Monotest		2					
		Virion/Serion SERION ELISA classic C. pneumoniae		1					
	Total:		29		-	-	-	-	


Specimen S003

Specimen S003 success rate




Specimen S003 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	11.1 %	88.9 %	55
	CpnAbG	2	2	100 %	25.9 %	74.1 %	54
	CpnAbM	2	2	100 %	0 %	100 %	53
	CpnAbA	-	-	-	-	100 %	29
	Total:	8	8	100 %	10.6 %	89.4 %	191

Specimen S003 Clinical interpretation




Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> No detectable C. pneumoniae antibodies		32		4	4	100 %	0 %	100 %
		A second sample is requested		6	-	-			
	<input type="radio"/> Most likely earlier infection/serological scar		4		-	-			0 %
	<input type="radio"/> Laboratory does not give clinical interpretation		19		-	-			-
		A second sample is requested		2	-	-			
		Referred to confirmation		1	-	-			
	Total:		55		4	4	100 %	11.1 %	88.9 %


Specimen S003 CpnAbG



Specimen S003 CpnAbM



Specimen S003 CpnAbA



OWN DEVICE: CHLA PNEU 2

CpnAbG	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		40		2	2	100 %	0 %	100 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1					
		Euroimmun Anti-C. pneumoniae ELISA		11					
		Euroimmun Anti-Chlamydia pneumoniae MIF		3					
		Focus Diagnostics Chlamydia MIF		2					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3					
		Novatec NovaLisa C. pneumoniae ELISA		3					
		<input checked="" type="radio"/> Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		5					
		Savyon diagnostics Chlamydia SeroFIA		1					
		Savyon Diagnostics SeroFIA C. pneumoniae		1					
		Siemens Novagnost		1					
		Vircell Chlamydophila pneumoniae ELISA		2					
		Vircell Chlamydophila pneumoniae VIRCLIA Monotest		4					
		Virion/Serion SERION ELISA classic C. pneumoniae		3					
	<input type="radio"/> Borderline		8		-				0 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		2					
		Focus Diagnostics Chlamydia MIF		1					
		Novatec NovaLisa C. pneumoniae ELISA		1					
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		1					

		Siemens Novagnost		1					
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		2					
	Positive		6		-				0 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1					
		Savyon Diagnostics SeroCP Quant kit		1					
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3					
	Total:		54		2	2	100 %	25.9 %	74.1 %

OWN DEVICE: CHLA PNEU 2

CpnAbM	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		53		2	2	100 %	0 %	100 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		4					
		Euroimmun Anti-C. pneumoniae ELISA		11					
		Euroimmun Anti-Chlamydia pneumoniae MIF		3					
		Focus Diagnostics Chlamydia MIF		2					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3					
		Novatec NovaLisa C. pneumoniae ELISA		4					
		<input checked="" type="radio"/> Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6					
		Savyon diagnostics Chlamydia SeroFIA		1					
		Savyon Diagnostics SeroCP		1					
		Savyon Diagnostics SeroFIA C. pneumoniae		1					
		Siemens Novagnost		2					
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3					
		Vircell Chlamydomphila pneumoniae ELISA		2					
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		6					
		Virion/Serion SERION ELISA classic C. pneumoniae		3					
	Total:		53		2	2	100 %	0 %	100 %

CpnAbA	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		29		-				100 %
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		2					
		Euroimmun Anti-C. pneumoniae ELISA		5					
		Euroimmun Anti-Chlamydia pneumoniae MIF		1					
		Focus Diagnostics Chlamydia MIF		2					
		Labsystems Diagnostics Chlamydia pneumoniae EIA		2					
		Novatec NovaLisa C. pneumoniae ELISA		2					
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		4					
		Savyon diagnostics Chlamydia SeroFIA		1					
		Savyon Diagnostics SeroCP		1					
		Siemens Novagnost		1					
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1					
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3					
		Vircell Chlamydomphila pneumoniae ELISA		1					
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		2					

		Virion/Serion SERION ELISA classic C. pneumoniae		1					
	Total:		29		-	-	-	-	100 %

Report Info**PARTICIPANTS**

Altogether 57 laboratories from 17 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Chlamydia pneumoniae, antibodies, March, 1-2023	57	53	93 %


Summary



Summary	AVR success rate
Specimen S001	94.3 %
Specimen S002	86.3 %
Specimen S003	89.4 %
Average:	90 %


Specimen S001

Specimen S001 success rate



Specimen S001 results	Responded	AVR success rate	Count
	Clinical interpretation	94.6 %	55
	CpnAbG	98.1 %	54
	CpnAbM	100 %	53
	CpnAbA	75.9 %	29
	Total:	94.3 %	191

Specimen S001 Clinical interpretation




Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	AVR success rate	Clinical interpretation Score	Further handling Score
	Most likely earlier infection/serological scar		35		100 %	4	
		A second sample is requested		7	-		-
		Referred to confirmation		1	-		-
	Most likely acute/recent C. pneumoniae infection		2		0 %	0	
		Referred to confirmation		1	-		-
		A second sample is requested		1	-		-
	Laboratory does not give clinical interpretation		18		-	-	
	Total:		55		94.6 %		

Specimen S001 CpnAbG




Borderline Positive

Specimen S001 CpnAbM



Negative

Specimen S001 CpnAbA



Negative Borderline Positive

CpnAbG	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Borderline		1		0 %	0
		Euroimmun Anti-Chlamydia pneumoniae MIF		1		
	Positive		53		100 %	2
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		4		
		Euroimmun Anti-C. pneumoniae ELISA		11		
		Euroimmun Anti-Chlamydia pneumoniae MIF		2		
		Focus Diagnostics Chlamydia MIF		3		
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3		
		Novatec NovaLisa C. pneumoniae ELISA		4		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6		
		Savyon diagnostics Chlamydia SeroFIA		1		
		Savyon Diagnostics SeroCP Quant kit		1		
		Savyon Diagnostics SeroFIA C. pneumoniae		1		
		Siemens Novagnost		2		
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1		
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3		
		Vircell Chlamydophila pneumoniae ELISA		2		
		Vircell Chlamydophila pneumoniae VIRCLIA Monotest		6		
		Virion/Serion SERION ELISA classic C. pneumoniae		3		
	Total:		54		98.1 %	


CpnAbM	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		53		100 %	2
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		4		
		Euroimmun Anti-C. pneumoniae ELISA		11		

	Euroimmun Anti-Chlamydia pneumoniae MIF		3		
	Focus Diagnostics Chlamydia MIF		2		
	Labsystems Diagnostics Chlamydia pneumoniae EIA		3		
	Novatec NovaLisa C. pneumoniae ELISA		4		
	Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6		
	Savyon diagnostics Chlamydia SeroFIA		1		
	Savyon Diagnostics SeroCP		1		
	Savyon Diagnostics SeroFIA C. pneumoniae		1		
	Siemens Novagnost		2		
	TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1		
	TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3		
	Vircell Chlamydoghila pneumoniae ELISA		2		
	Vircell Chlamydoghila pneumoniae VIRCLIA Monotest		6		
	Virion/Serion SERION ELISA classic C. pneumoniae		3		
	Total:		53		100 %

CpnAbA	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		22		100 %	2
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1		
		Euroimmun Anti-C. pneumoniae ELISA		5		
		Euroimmun Anti-Chlamydia pneumoniae MIF		1		
		Labsystems Diagnostics Chlamydia pneumoniae EIA		2		
		Novatec NovaLisa C. pneumoniae ELISA		2		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		4		
		Savyon Diagnostics SeroCP		1		
		Siemens Novagnost		1		
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1		
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3		
		Virion/Serion SERION ELISA classic C. pneumoniae		1		
	Borderline		3		0 %	0
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1		
		Savyon diagnostics Chlamydia SeroFIA		1		
		Vircell Chlamydoghila pneumoniae ELISA		1		
	Positive		4		0 %	0
		Focus Diagnostics Chlamydia MIF		2		
		Vircell Chlamydoghila pneumoniae VIRCLIA Monotest		2		
	Total:		29		75.9 %	


Specimen S002

Specimen S002 success rate




Specimen S002 results	Responded	AVR success rate	Count
	Clinical interpretation	76.3 %	55
	CpnAbG	100 %	54
	CpnAbM	86.8 %	53
	CpnAbA	-	29
	Total:	86.3 %	191

Specimen S002 Clinical interpretation




Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	AVR success rate	Clinical interpretation Score	Further handling Score
	Most likely earlier infection/serological scar		29		100 %	4	
		A second sample is requested		7	-		-
	Most likely acute/recent C. pneumoniae infection		9		0 %	0	
		Referred to confirmation		3	-		-
		A second sample is requested		3	-		-
	Laboratory does not give clinical interpretation		17		-	-	
	Total:		55		76.3 %		

Specimen S002 CpnAbG




Positive

Specimen S002 CpnAbM



Negative Borderline Positive

Specimen S002 CpnAbA



Negative Borderline Positive

CpnAbG	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		54		100 %	2
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		4		
		Euroimmun Anti-C. pneumoniae ELISA		11		
		Euroimmun Anti-Chlamydia pneumoniae MIF		3		
		Focus Diagnostics Chlamydia MIF		3		
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3		
		Novatec NovaLisa C. pneumoniae ELISA		4		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6		
		Savyon diagnostics Chlamydia SeroFIA		1		
		Savyon Diagnostics SeroCP Quant kit		1		
		Savyon Diagnostics SeroFIA C. pneumoniae		1		
		Siemens Novagnost		2		
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1		
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3		
		Vircell Chlamydomphila pneumoniae ELISA		2		
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		6		
		Virion/Serion SERION ELISA classic C. pneumoniae		3		
	Total:		54		100 %	


CpnAbM	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		46		100 %	2
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		3		
		Euroimmun Anti-C. pneumoniae ELISA		11		
		Euroimmun Anti-Chlamydia pneumoniae MIF		3		
		Focus Diagnostics Chlamydia MIF		2		

		Labsystems Diagnostics Chlamydia pneumoniae EIA		3		
		Novatec NovaLisa C. pneumoniae ELISA		4		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6		
		Savyon diagnostics Chlamydia SeroFIA		1		
		Savyon Diagnostics SeroCP		1		
		Savyon Diagnostics SeroFIA C. pneumoniae		1		
		Siemens Novagnost		2		
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1		
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3		
		Vircell Chlamydomphila pneumoniae ELISA		1		
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		1		
		Virion/Serion SERION ELISA classic C. pneumoniae		3		
	Borderline		3		0 %	0
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1		
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		2		
	Positive		4		0 %	0
		Vircell Chlamydomphila pneumoniae ELISA		1		
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		3		
	Total:		53		86.8 %	

CpnAbA	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		10		-	-
		Euroimmun Anti-C. pneumoniae ELISA		5		
		Labsystems Diagnostics Chlamydia pneumoniae EIA		1		
		Novatec NovaLisa C. pneumoniae ELISA		1		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		1		
		Savyon Diagnostics SeroCP		1		
		Siemens Novagnost		1		
	Borderline		5		-	-
		Euroimmun Anti-Chlamydia pneumoniae MIF		1		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		2		
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		2		
	Positive		14		-	-
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		2		
		Focus Diagnostics Chlamydia MIF		2		
		Labsystems Diagnostics Chlamydia pneumoniae EIA		1		
		Novatec NovaLisa C. pneumoniae ELISA		1		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		1		
		Savyon diagnostics Chlamydia SeroFIA		1		
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1		
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		1		
		Vircell Chlamydomphila pneumoniae ELISA		1		
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		2		
		Virion/Serion SERION ELISA classic C. pneumoniae		1		
	Total:		29			


Specimen S003

Specimen S003 success rate




Specimen S003 results	Responded	AVR success rate	Count
	Clinical interpretation	88.9 %	55
	CpnAbG	74.1 %	54
	CpnAbM	100 %	53
	CpnAbA	100 %	29
	Total:	89.4 %	191

Specimen S003 Clinical interpretation




Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	AVR success rate	Clinical interpretation Score	Further handling Score
	No detectable C. pneumoniae antibodies		32		100 %	4	
		A second sample is requested		6	-		-
	Most likely earlier infection/serological scar		4		0 %	0	
	Laboratory does not give clinical interpretation		19		-	-	
		A second sample is requested		2	-		-
		Referred to confirmation		1	-		-
	Total:		55		88.9 %		


Specimen S003 CpnAbG



Specimen S003 CpnAbM



Specimen S003 CpnAbA



CpnAbG	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		40		100 %	2
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1		
		Euroimmun Anti-C. pneumoniae ELISA		11		
		Euroimmun Anti-Chlamydia pneumoniae MIF		3		
		Focus Diagnostics Chlamydia MIF		2		
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3		
		Novatec NovaLisa C. pneumoniae ELISA		3		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		5		
		Savyon diagnostics Chlamydia SeroFIA		1		
		Savyon Diagnostics SeroFIA C. pneumoniae		1		
		Siemens Novagnost		1		
		Vircell Chlamydophila pneumoniae ELISA		2		
		Vircell Chlamydophila pneumoniae VIRCLIA Monotest		4		
		Virion/Serion SERION ELISA classic C. pneumoniae		3		
	Borderline		8		0 %	0
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		2		
		Focus Diagnostics Chlamydia MIF		1		
		Novatec NovaLisa C. pneumoniae ELISA		1		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		1		
		Siemens Novagnost		1		
		Vircell Chlamydophila pneumoniae VIRCLIA Monotest		2		
	Positive		6		0 %	0
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		1		
		Savyon Diagnostics SeroCP Quant kit		1		
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1		

		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3		
	Total:		54		74.1 %	

CpnAbM	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		53		100 %	2
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		4		
		Euroimmun Anti-C. pneumoniae ELISA		11		
		Euroimmun Anti-Chlamydia pneumoniae MIF		3		
		Focus Diagnostics Chlamydia MIF		2		
		Labsystems Diagnostics Chlamydia pneumoniae EIA		3		
		Novatec NovaLisa C. pneumoniae ELISA		4		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		6		
		Savyon diagnostics Chlamydia SeroFIA		1		
		Savyon Diagnostics SeroCP		1		
		Savyon Diagnostics SeroFIA C. pneumoniae		1		
		Siemens Novagnost		2		
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1		
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3		
		Vircell Chlamydomphila pneumoniae ELISA		2		
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		6		
		Virion/Serion SERION ELISA classic C. pneumoniae		3		
	Total:		53		100 %	

CpnAbA	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		29		100 %	2
		DIESSE Chorus CHLAMYDOPHILA PNEUMONIAE		2		
		Euroimmun Anti-C. pneumoniae ELISA		5		
		Euroimmun Anti-Chlamydia pneumoniae MIF		1		
		Focus Diagnostics Chlamydia MIF		2		
		Labsystems Diagnostics Chlamydia pneumoniae EIA		2		
		Novatec NovaLisa C. pneumoniae ELISA		2		
		Orgentec Diagnostika Anti-Chlamydia pneumoniae Abs		4		
		Savyon diagnostics Chlamydia SeroFIA		1		
		Savyon Diagnostics SeroCP		1		
		Siemens Novagnost		1		
		TestLine Clinical Diagnostics EIA Chlamydia pneumoniae		1		
		TestLine Clinical Diagnostics SmartEIA Chlamydia pneumoniae		3		
		Vircell Chlamydomphila pneumoniae ELISA		1		
		Vircell Chlamydomphila pneumoniae VIRCLIA Monotest		2		
		Virion/Serion SERION ELISA classic C. pneumoniae		1		
	Total:		29		100 %	

Report Info**PARTICIPANTS**

Altogether 57 laboratories from 17 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

External Quality Assessment Scheme

***Chlamydia pneumoniae*, antibodies** **Round 1, 2023**

Specimens

Samples of this EQA round were human plasma or serum. The homogeneity of samples was ensured during the sample preparation. The antibodies are known to be stable and there are no special requirements for their handling or storage. The samples were suitable for the external quality assessment scheme. The materials were sent without temperature control packaging.

The expected results were as follows:

Sample S001 (LQ757423011)

CpnAbG	Positive
CpnAbM	Negative
CpnAbA	Negative
Clinical interpretation	Most likely earlier infection/serological scar

Sample S002 (LQ757423012)

CpnAbG	Positive
CpnAbM	Negative
CpnAbA	Negative
Clinical interpretation	Most likely earlier infection/serological scar

Sample S003 (LQ757423013)

CpnAbG	Negative
CpnAbM	Negative
CpnAbA	Negative
Clinical interpretation	No detectable <i>C. pneumoniae</i> antibodies

Pre-test method: Labsystems Diagnostics *Chlamydia pneumoniae* IgG/IgM/IgA EIA.

Report info

Please see the description of the data analysis on the last page of the laboratory-specific reports and global reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – Expert

Sample S001

IgG class antibodies were detected in the pretest, so this most likely represents a previous infection/serological scar (IgG+, IgM-, IgA-). IgG and IgM antibody results and responses were as expected. Four participants detected IgA class antibodies in the sample and three laboratories reported a borderline IgA result.

Sample S002

Similarly to sample S001, IgG class antibodies but no IgM class antibodies were detected in the pretest. The finding suggests a previous infection/serological scar (IgG+, IgM-, IgA-/+). IgG and IgM antibody results and responses were often reported as expected. Seven laboratories reported IgM class antibodies as positive/borderline (using three different tests). In general, two of the three tests, however, gave expected results in ≥50% of the cases.

Sample S003

The sample was negative in the preliminary test (IgG-, IgM-, IgA-). Eight participants reported IgG response as borderline. Other participants who used

2023-05-04

FINAL REPORT

Product no. 5620

Subcontracting: Sample pretesting

Samples sent	2023-03-14
Round closed	2023-04-05
Expected results	2023-04-06
Final report	2023-05-04

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator
Marsa Järvenpää
marsa.jarvenpaa@labquality.fi

EQA Coordinator
Outi Rauta
outi.rauta@labquality.fi

Expert

MD, PhD Mirja Puolakkainen,
Department of Virology,
University of Helsinki and
Helsinki University Hospital,
Finland

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200

Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com



the same tests reported the sample most often as negative. Six participants responded that the sample was IgG positive. The IgM and IgA of the sample were always answered as negative.

Exceptions in scoring

IgA test results were not scored in sample S002 due to dispersion of the results.

End of report

Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures, or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipment or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipment or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.